Topline data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – onasemnogene abeparvovec (OAV101 IT) – which could become ...

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

HMNC has completed the subject randomisation in its Phase IIb OLIVE trial of BH-200 for major depressive disorder (MDD) treatment.

The Phase III trial follows the company’s previous Phase I trial, which saw 12 participants dosed with Bemdaneprocel. Credit: Shutterstock / Yuri A US-based Bayer subsidiary BlueRock Therapeutics has ...

Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.